The USPTO’s Patent Trial and Appeal Board has ruled in favor of the Broad Institute of MIT and Harvard retaining intellectual property rights covered by its patents for CRISPR gene-editing technology.
September 8, 2015|
March 6, 2015|
The US Food and Drug Administration approves Sandoz’s Zarxio, a biosimilar to Amgen’s filgrastim, which is mainly prescribed for cancer patients.
February 5, 2015|
The pharmaceutical giant is purchasing the injectable drugmaker for about $15 billion.
June 29, 2012|
The Supreme Court's decision to uphold President Barack Obama's health care reform law contains key provisions that will impact US science funding in the years to come.
June 1, 2012|
As biologic drug patents begin to expire, generic versions will hit the market—but how will they be regulated?
Page 1 of 1